Oncology
Excerpt from the Press Release: Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone Improved responses seen across all histology subgroups including populations of patients unresponsive to other therapies Dr. David O’Malley to present data in an oral presentation…
Read More
Excerpt from the Press Release: SLATE version (v) 1, Gritstone’s “off the-shelf” neoantigen immunotherapy (including KRAS, TP53 mutations), elicited multiple molecular responses and an unconfirmed RECIST radiologic response in patients with NSCLC who had progressed on prior immunotherapy SLATE v2 (a mutant KRAS-focused version), which is optimized for increased immune response, has been administered to…
Read More
Study conducted with investigators at Dana-Farber Cancer Institute showed ctDNA changes pre- and post-ICI therapy associated with resistance to treatment; Suggests liquid biopsy may be a useful tool for personalizing immunotherapy in patients with metastatic urothelial carcinoma Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Precision oncology company Lucence, in collaboration with researchers at Dana-Farber…
Read More
KIN-3248 demonstrates highly-selective, potent, and broad-spectrum activity against mutations in both the FGFR2 and FGFR3 kinase domains – including acquired gatekeeper, molecular brake, and activation loop resistance mutations Excerpt from the Press Release: SAN FRANCISCO and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on…
Read More
Personalized Therapy Biosimulation Identifies Novel Biomarkers that Predict Drug and Immunotherapy Response in Patients with NSCLC Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced that results from patient stratification studies using the Cellworks Computational…
Read More
Excerpt from the Press Release: SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be…
Read More
Excerpt from the Press Release: Researchers at the University of California, San Diego (UCSD) have grown miniature human lungs in a lab dish that they say come the closest to mimicking the real thing—complete with all the myriad cell types found in the body. The small organoids of human tissue could help rapidly iterate the…
Read More
Excerpt from the Press Release: RINCETON, N.J.–(BUSINESS WIRE)–The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in the…
Read More
Excerpt from the Press Release: One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff – – Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET – PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE…
Read More Excerpt from the Press Release: Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to HER2+ breast cancer, a common and deadly form of cancer – Affinia Therapeutics to use its proprietary technologies and capsids with improved properties to bring the promise of gene therapy to…
Read More